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Lactic acid and short chain fatty acids (SCFAs) produced by vaginal microbiota
have reported antimicrobial and immune modulatory activities indicating their potential
as biomarkers of disease and/or disease susceptibility. In asymptomatic women of
reproductive-age the vaginal microbiota is comprised of lactic acid-producing bacteria
that are primarily responsible for the production of lactic acid present at ∼110mM and
acidifying the vaginal milieu to pH ∼3.5. In contrast, bacterial vaginosis (BV), a dysbiosis
of the vaginal microbiota, is characterized by decreased lactic acid-producing microbiota
and increased diverse anaerobic bacteria accompanied by an elevated pH>4.5. BV
is also characterized by a dramatic loss of lactic acid and greater concentrations of
mixed SCFAs including acetate, propionate, butyrate, and succinate. Notably women
with lactic acid-producingmicrobiota havemore favorable reproductive and sexual health
outcomes compared to women with BV. Regarding the latter, BV is associated with
increased susceptibility to sexually transmitted infections (STIs) including HIV. In vitro
studies demonstrate that lactic acid produced by vaginal microbiota has microbicidal
and virucidal activities that may protect against STIs and endogenous opportunistic
bacteria as well as immune modulatory properties that require further characterization
with regard to their effects on the vaginal mucosa. In contrast, BV-associated SCFAs
have far less antimicrobial activity with the potential to contribute to a pro-inflammatory
vaginal environment. Here we review the composition of lactic acid and SCFAs in
respective states of eubiosis (non-BV) or dysbiosis (BV), their effects on susceptibility
to bacterial/viral STIs and whether they have inherent microbicidal/virucidal and immune
modulatory properties. We also explore their potential as biomarkers for the presence
and/or increased susceptibility to STIs.
Keywords: lactic acid, short chain fatty acids, bacterial vaginosis, lactobacilli, vaginal microbiota, metabolites,
microbiome
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Introduction
The lower female reproductive tract, specifically the vagina and
ectocervix, is considered a formidable chemical and physical
barrier to exogenous invading organisms, in part due to the
structure of the stratified vaginal epithelium and the presence
of cervicovaginal fluid (CVF). Eubiotic viscoelastic CVF acts
as an effective lubricant, facilitates the trapping of exogenous
organisms and, acts as an acidified medium in which there
is an arsenal of antimicrobial molecules (antibodies, defensins
etc.). Importantly, this mucosal layer (mucus and layers of
dead epithelial cells) also enables the adhesion of mutualistic
vaginal microbiota (Boris et al., 1998). In asymptomatic women,
microbiota acidify the vagina through lactic acid-production
whilst bacterial vaginosis-associated bacteria (BVAB) produce
many short chain fatty acids (SCFAs) that contribute the
development of a dysbiotic vaginal environment (Aroutcheva
et al., 2001a,b; Valore et al., 2002; Yeoman et al., 2013). The
study of asymptomatic reproductive-age women has revealed
that vaginal microbiota are unique to each woman but are largely
dominated by lactic acid-producing bacteria, most often from
the Lactobacillus genus (Verhelst et al., 2004; Fredricks et al.,
2005; Ravel et al., 2011). Despite the differences in bacterial
composition of vaginal communities, it seems that acidifying
the vaginal milieu via generation of organic acid metabolites,
predominantly lactic acid, is a conserved function (Ravel et al.,
2011; Gajer et al., 2012). Humans are unique among primates in
supporting lactic acid-producing vaginal microbiota (Mirmonsef
et al., 2012a; Yildirim et al., 2014), particularly lactobacilli, which
are largely responsible for acidifying the vaginal milieu with
∼110mM of lactic acid by anaerobic glycolysis of glycogen
released from shed and shedding vaginal epithelial cells (Stanek
et al., 1992; Boskey et al., 1999, 2001). This ultimately acidifies the
vagina to an average pH ∼3.5 (Fox et al., 1973; O’Hanlon et al.,
2013), with both D and L optical isomers of lactic acid that differ
in their arrangement of the same chemical components around
a central carbon. The D/L ratio of lactic acid isomers matches
the ratio produced by lactobacilli cultured from the same vaginal
sample of CVF (Boskey et al., 2001) strongly indicating that lactic
acid produced by lactobacilli is responsible for vaginal acidity. In
women with lactobacillus-dominated flora, the vaginal pH tightly
correlates with lactic acid concentration in CVF (O’Hanlon
et al., 2013) suggesting that lactic acid is likely responsible for
generating the protective acidic environment considered to be so
important for antimicrobial activity.
Bacterial vaginosis (BV) is largely defined as a dysbiosis
of the vaginal microbiome and is the most common and
enigmatic vaginal condition in reproductive-age women. BV is
characterized by a loss of lactic acid-producing bacteria and
an increase in the number and diversity of anaerobic bacteria.
Symptoms include an elevated vaginal pH >4.5 and malodorous
abnormal discharge (Spiegel et al., 1980; Ling et al., 2010).
BV is commonly diagnosed using two methods, the Amsel
criteria or the Nugent Gram stain scoring method. A positive
diagnosis of BV requires that three of the four Amsel criteria be
satisfied; thin homogenous discharge, pH >4.5, amine odor and
shed epithelial cells covered with bacteria (clue cells), whereas
the Nugent Gram stain scoring method enumerates bacterial
morphotypes associated with health (Gram-positive lactobacilli)
and BV-associated morphotypes (Gram-variable rods). A low
Nugent score (0–3) is indicative of healthy microbiota and a
high Nugent score (7–10) is a positive diagnosis for BV (Nugent
et al., 1991). Using this method, women diagnosed with BV
may have a high Nugent score in the presence (symptomatic
BV) or the absence (asymptomatic BV) of the aforementioned
symptoms. BV risk factors commonly include menses, sexual
activities and hygiene practices (Schwebke et al., 1999; Jespers
et al., 2012; Srinivasan et al., 2012; Yeoman et al., 2013). BV
is estimated to affect 5–15% Caucasian women, 20–30% Asian
women,∼30% of Hispanic women, and 45–55% of Black women
(Sewankambo et al., 1997; Schneider et al., 1998; Allsworth and
Peipert, 2007; Bhalla et al., 2007; Fang et al., 2007; Koumans
et al., 2007; Oliveira et al., 2007; Akinbiyi et al., 2008; Thoma
et al., 2011). This is mirrored by global BV prevalence estimates
showing a general trend toward high prevalence in Africa and
low prevalence in Europe and Asia (Kenyon et al., 2013). BV
plays a significant role in public health due to is association
with various reproductive sequelae (Hillier et al., 1995; Donders
et al., 2000; Ness et al., 2005; Leitich and Kiss, 2007) and
increased susceptibility to sexually transmitted infections (STIs)
including the human immunodeficiency virus (HIV) (Taha et al.,
1998; Cu-Uvin et al., 2001; Cherpes et al., 2003; Wiesenfeld
et al., 2003; Allsworth and Peipert, 2007; Coleman et al.,
2007; Kaul et al., 2007; Atashili et al., 2008; Cohen et al.,
2012).
Studies investigating the metabolites produced by
lactobacillus-dominated microbiota and the polymicrobial
BV states have observed a striking loss of lactic acid and a
shift toward mixed SCFA (SCFA) production during BV (Al-
Mushrif et al., 2000; Mirmonsef et al., 2011, 2012c; Gajer et al.,
2012; O’Hanlon et al., 2013; Yeoman et al., 2013). Generally,
acetate is the predominant metabolite in the CVF of women
with symptomatic BV in addition to increased concentrations
of propionate, butyrate and succinate (Stanek et al., 1992;
Chaudry et al., 2004). Lactic acid and SCFA metabolites found
in CVF have reported microbicidal, virucidal, and immune
modulatory activities indicating their potential as biomarkers
of disease and/or disease susceptibility (Al-Mushrif et al., 2000;
O’Hanlon et al., 2011; Mirmonsef et al., 2012c; Aldunate et al.,
2013).
The Vaginal Microbiota
Albert Döderlein first described the presence of Gram-positive
bacilli and low vaginal pH in the CVF of healthy reproductive-
age women in 1892 (Döderlein, 1892). Later known as the
Lactobacillus acidophilus complex (Thomas, 1928), lactobacilli
came to be regarded as the foundation of healthy vaginal
microbiota. In contrast, a paucity of lactobacilli and an
increase in other bacterial morphotypes could be associated
with symptomatic vaginal discharge (Döderlein, 1892; Curtis,
1914; Spiegel et al., 1980; Amsel et al., 1983; Jokipii et al.,
1986). Many of the concepts of what could be considered
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healthy or unhealthy were based on distinctions made from
microscopy and culture-dependent techniques; however, many
also acknowledged that fastidious microbiota members were
unlikely to be cultured. Nonetheless, the paradigm that
lactobacilli equate to a healthy vaginal ecosystem became
established and the true complexity of the microbiome
would remain obscure until the advent of culture-independent
molecular techniques.
Cross-sectional Studies of the Vaginal
Microbiome in Healthy Asymptomatic Women
Early cross-sectional studies revealed that the microbiota of
asymptomatic reproductive-age women are indeed dominated by
lactic acid-producing bacteria, primarily Lactobacillus (Verhelst
et al., 2004; Zhou et al., 2004, 2007; Fredricks et al., 2005; Oakley
et al., 2008). New members of the vaginal microbiome were also
identified including Atopobium and Lactobacillus iners (Burton
and Reid, 2002; Zhou et al., 2004). Later, Ravel et al. (2011)
employed next generation sequencing in their landmark study
to characterize the vaginal microbiomes of 396 ethnically diverse
women of reproductive-age, revealing five core microbiomes
termed community state types (CSTs). Four CSTs were described
according to the dominant Lactobacillus species; L. crispatus, L.
gasseri, L. iners, and L. jensenii corresponding to CST I, II, III, and
V (Table 1). Collectively, Lactobacillus was the dominant species
in 73% of the vaginal communities in this study group of healthy
women. These four Lactobacillus species appear to represent the
most prevalent bacteria in reproductive-age women, consistent
with many previous investigations (Table 1) (Zhou et al., 2009,
2010; Forney et al., 2010; Ravel et al., 2011; Yoshimura et al.,
2011; Martin et al., 2012; Smith et al., 2012). Importantly, this
study also highlighted that 27% of women had communities
characterized by microbial diversity assigned to CST IV (Ravel
et al., 2011). Here, two subgroups IV-A or IV-B contained
modest or no lactobacilli, respectively, in addition to several
anaerobic bacteria known to produce lactic acid (Table 1). These
community members are primarily strict or facultative anaerobes
some of which are traditionally associated with dysbiosis, as in
BV and include; Atopobium, Gardnerella Prevotella, Mobiluncus,
Megasphaera, Dialister, Sneathia, Streptococcus, Pseudomonas,
Leptotrichia, and Aerococcus amongst others. Although there is
some debate as to whether these women are actually healthy
and not asymptomatic for BV, it is worth noting a multitude of
previous studies using various molecular methods also identified
at least one group in their phylogenetic analyses that is analogous
to the microbially diverse CST IV (Kim et al., 2009; Yamamoto
et al., 2009; Forney et al., 2010; Zhou et al., 2010; Jespers et al.,
2012). Therefore, it seems that bacteria traditionally associated
with BV due to a high bacterial load, are likely members of
eubiotic vaginal communities that have been overlooked in the
past (Antonio et al., 1999; Pavlova et al., 2002; Zhou et al.,
2004; Biagi et al., 2009; Yamamoto et al., 2009). Recent studies
now show that 20–30% of women have diverse microbiomes not
dominated by Lactobacillus that are not classically considered
normal or healthy (Zhou et al., 2004, 2007, 2010; Srinivasan and
Fredricks, 2008; Schellenberg et al., 2009; Ravel et al., 2011, 2013;
Gajer et al., 2012).
Temporal Studies of the Vaginal Microbiome and
Community Dynamics using Molecular
Characterization
Numerous cross-sectional studies have helped revise our
understanding of bacterial communities in the vaginal
ecosystem. However, this ecosystem is not static, there are
many disturbances through continual eﬄux of CVF containing
bacteria, antimicrobials, and sloughed epithelial cells from
constant renewal of the vaginal epithelium. There are also
cyclical changes in estrogen, glycogen content, pH and menses
TABLE 1 | Microbial communities and metabolite spectrum in the vaginal ecosystem and their proposed relationship to risks of adverse sexual and
reproductive outcomes.
Community State Type (CSTs) pH Metabolite profile
I L. crispatus 4.0a
II L. gasseri 5.0a
V L. jensensii 4.7a
III L. iners (ubiquitous regardless of BV status) 4.4a
IV-A Modest levels of L. crispatus, L. iners or other
Lactobacillus sp. with low proportions of
Streptococcus, Anaerococcus,
Corynebacterium and Finegoldia
5.3a
IV-B Relatively high levels of Atopobium,
Gardnerella, Mobiluncus, Peptoniphilus,
Sneathia, Prevotella and several other taxa of
BVAB
BV Polymicrobial
Increased diversity and bacterial load of BVAB
>4.5
apH was measured using a VpH glove test strip with pH determined according to color chart (Ravel et al., 2011) pH is likely to be lower if measured under vaginal hypoxic conditions
with a pH electrode (O’Hanlon et al., 2013).
Frontiers in Physiology | www.frontiersin.org 3 June 2015 | Volume 6 | Article 164
Aldunate et al. Activity of vaginal microbiota SCFAs
as well as the introduction of exogenous bacteria due to human
activities such as sex and hygiene practices (Srinivasan et al.,
2010; Gajer et al., 2012; Yeoman et al., 2013). Therefore, studies
that analyze samples from a single time point merely offer a
glimpse of the microbiome as it is affected by and responds to
these intrinsic and extrinsic disturbances. The dynamic nature of
the vaginal ecosystem can be assessed with temporal longitudinal
studies that complement cross-sectional findings by evaluating
shifts in community composition and structure, and their
stability over time.
Overall, longitudinal studies reveal that the temporal
dynamics of vaginal microbiota is unique to each reproductive-
age woman (Santiago et al., 2011; Gajer et al., 2012; Hickey
et al., 2013), with some possessing relatively stable communities
(Wertz et al., 2008; Biagi et al., 2009; Santiago et al., 2011; Gajer
et al., 2012; Jespers et al., 2012) and others experiencing brief
albeit dramatic shifts (Brotman et al., 2010b; Gajer et al., 2012;
Ravel et al., 2013). Altered community dynamics were commonly
associated with menses (Srinivasan et al., 2010; Santiago et al.,
2011; Gajer et al., 2012; Jespers et al., 2012; Hickey et al., 2013),
sex (Srinivasan et al., 2010; Jespers et al., 2012; Santiago et al.,
2012), and bacterial composition within a CST (Verstraelen et al.,
2009; Gajer et al., 2012). Conversely, a high level of estrogen
alone or estrogen and progesterone were associated with greater
community stability (Gajer et al., 2012); this effect was also seen in
pregnant women with high estrogen levels (Romero et al., 2014).
Recent studies have highlighted that shifts in vaginal
community composition seem to be preferential (Verstraelen
et al., 2009; Gajer et al., 2012; Smith et al., 2012; Romero
et al., 2014). L. crispatus (CST I, Table 1) has been reported to
experience few transitions to other CSTs and seems to be quite
stable and promote vaginal community stability (Verstraelen
et al., 2009; Gajer et al., 2012). L. crispatus is common in
Caucasian and Asian women and less so in Black and Hispanic
women (Zhou et al., 2004; Ravel et al., 2011; Jespers et al., 2012),
and is present primarily in healthy asymptomatic women whilst
L. iners is ubiquitous, even in women with dysbiosis such as
BV (Verhelst et al., 2004; Zozaya-Hinchliffe et al., 2008; Biagi
et al., 2009). It is therefore not surprising that microbiomes
dominated by L. iners (CST III, Table 1) exhibit the greatest
variation in composition and stability. One study reported
that L. iners was twice as likely to transition to the diverse
CST IV-B than IV-A (Gajer et al., 2012) meanwhile another
concluded that L. gasseri/L. iners signify a predisposition to the
occurrence of dysbiotic vaginal bacteria (Verstraelen et al., 2009).
However, little is known about L. gasseri and L. jensenii and non
lactobacillus-dominated microbiomes (CST IV, Table 1), because
they are less prevalent in reproductive-age women. The observed
shifts in vaginal communities has led to the proposition of an
ecological hypothesis describing the maintenance of equilibrium
in the vagina by transitioning between alternative communities
whereby not all are favorable or conducive to maintaining
community function (Ravel et al., 2011; Gajer et al., 2012).
Role of Lactic Acid Producing Vaginal Microbiota
in the Maintenance of Community Function
Previous studies have cited the production of lactic acid
as a major conserved characteristic maintained through the
functional redundancy exhibited by members of a transitioning
community (Zhou et al., 2004; Linhares et al., 2010; Ravel
et al., 2011; Gajer et al., 2012). This finding lends credence to
the notion that several lactic acid-producing microbiota act to
conserve community function and that variability in community
composition is not necessarily a precursor to dysbiosis that
leads to pathology. The vagina is subject to many disturbances;
it is therefore not surprising that the ecosystem has evolved
to accommodate changes in community composition through
divergent organisms that perform a common function since
vaginal homeostasis is more likely to be maintained. The range
of lactic acid-producing bacteria commonly found in the vagina
may therefore represent a group of particularly adept allelopathic
organisms that use acid fermentation products, especially lactic
acid, to suppress or otherwise outcompete other organisms
and interact with the host in a manner that favors their
competition. It follows that different community types may
have varying levels of functionally redundant microbiota that
maintain community performance; hence may exhibit varying
degrees of resilience in the face of disturbances that could
influence susceptibility to disease when combined with host
determinants (Table 1). The incredibly complex and dynamic
nature of the microbiome brings to light the numerous
obstacles that must be surmounted by researchers who seek
to uncover factors that elicit changes in the microbiome
and consequently maintain eubiosis or lead to a dysbiotic
state associated with risks of disease. It also highlights the
need to move away from merely identifying what organisms
are present toward determining their metabolic capacity,
antimicrobial, immune modulatory effects, and function in the
microbiome.
Immune Modulation by the Vaginal Microbiome
The vaginal mucosal epithelium acts both as a physical
barrier and immunological mediator providing the first defense
against potential infections (Kaushic, 2011; Anderson et al.,
2014). Mucosal epithelia generally comprise multiple layers
of rarely keratinized stratified squamous epithelium that rests
on a lamina propria where the uppermost apical layers lack
tight junctions (Blaskewicz et al., 2011; Anderson et al.,
2014). These layers are permeable to water, soluble proteins,
viruses, and penetrable by vaginal microbiota as well as
cellular (e.g., CD4+ T cells and macrophages) and molecular
mediators of the immune system (e.g., cytokines) (Blaskewicz
et al., 2011; Carias et al., 2013; Politch et al., 2014).
The vagina and endocervix provide immunological defenses
by conferring tolerance to microbes, maintaining epithelial
integrity, and recruiting and supporting immune cells (Fichorova
and Anderson, 1999). As the front line of immune defense,
epithelial cells express pattern recognition receptors (PRRs)
including Toll-like receptors (TLRs) that respond to microbe-
or pathogen-associated molecular patterns (MAMPs/PAMPs)
(Table 2) by secreting cytokines and chemokines, antimicrobial
peptides and other immune factors (Fichorova and Anderson,
1999; Herbst-Kralovetz et al., 2008; Kaushic, 2011; Rose et al.,
2012). The pro-inflammatory response elicited by pathogens
is normally required to control infections (Sandler et al.,
2014). However, vaginal mucosal inflammation can promote
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TABLE 2 | The effects of lactic acid and BV-associated SCFAs on TLR responses.
PRR Common MAMPs/PAMPs Organism
recognized
Effect of lactic acid or SCFAs
TLR1a,b
Lipopeptides, lipopolysaccharide, peptidoglycan,
flagellin
Bacteria
ND
TLR2a,b
Acetate and butyrate induced production of pro-inflammatory
cytokines IL-8, TNFα and IL-1β from human PBMCs and potentiated
pro-inflammatory responses to TLR2 ligandsc
TLR6a,b ND
TLR3a,b Double stranded ribonucleic acid (ds RNA) Virus In the VK2/E6E7 human vaginal epithelial cell line, L-lactic acid and poly
I:C treatment led to the production of the pro-inflammatory immune
mediators IL-8 and IL-1β in a standard tissue culture plate setupd.
TLR4a,b Lipopolysaccharide
Lipoteichoic acid
Viral envelope proteins
Protozoal phospholipids
Gram negative bacteria
Gram positive bacteria
Virus
Trichomonas vaginalis
L-lactic acid and lipopolysaccharide increased IL-23 production from
human PBMCs, may lead to preferential stimulation of Th17
T-lymphocytes that protect mucosa from extracellular bacteriae
TLR5a,b Flagellin Bacteria ND
TLR7a,b
Single stranded ribonucleic acid (ss RNA) Virus
Acetate and butyrate induced the production of pro-inflammatory
cytokines of IL-8, TNFα and IL-1β from human PBMCs and potentiated
pro-inflammatory responses to TLR7 ligandsc
TLR8a,b ND
TLR9a,b Un-methylated components of nucleic acid Bacteria
Virus
ND
ND-Not determined.
aNasu and Narahara (2010).
bHerbst-Kralovetz et al. (2008).
cMirmonsef et al. (2012c).
dMossop et al. (2011).
eWitkin et al. (2011).
transmission of viral STIs, such as HIV, by compromising
epithelium integrity (Nazli et al., 2010) and by recruiting and
activating HIV target cells (Li et al., 2009). Epithelial cell-
derived immune mediators have pivotal roles in cell recruitment,
immune regulation and tissue repair (Fichorova and Anderson,
1999). Given the intimate contact between the microbiota
and their acid metabolites with the vaginal epithelium it is
important to study how these interactions modulate mucosal
immunity.
Lactic acid-producing bacteria are known to maintain
homeostasis by attenuating inflammation in the gut and by
preserving gut barrier function (Zeuthen et al., 2008; Donato
et al., 2010; Santos Rocha et al., 2012; Castillo et al., 2013; Perez-
Santiago et al., 2013). Vaginal microbiota are reported to mediate
immune modulatory effects on the vaginal mucosa (Al-Mushrif
et al., 2000; Sakai et al., 2004; Nikolaitchouk et al., 2008; Joo
et al., 2011; Kyongo et al., 2012). Studies in women from distinct
geographical regions colonized with lactobacillus-dominated
microbiota suggest an absence of vaginal inflammation, which
may in part depend on the dominant Lactobacillus species.
Specifically, vaginal lactobacilli are associated with lower levels
of pro-inflammatory cytokines in CVF (e.g., IL-1α and/or IL-
8) (Sakai et al., 2004; Nikolaitchouk et al., 2008; Kyongo et al.,
2012), and in the case of L. iners, higher levels of secretory
leukocyte peptidase inhibitor (SLPI) (Nikolaitchouk et al., 2008),
an antimicrobial peptide normally depleted in women with
dysbiosis such as BV (Draper et al., 2000; Mitchell et al.,
2009; Balkus et al., 2010; Dezzutti et al., 2011). The presence
of L. crispatus and L. jensenii were negatively associated with
cellular inflammatory markers (Kyongo et al., 2012). In contrast,
a study in adolescents failed to show differences for most
cytokines in CVF from young women with dysbiosis compared
to women with lactobacillus-dominated microbiota (Alvarez-
Olmos et al., 2004), although further studies in distinct cohorts
are required. Largely consistent with in vivo observations, in vitro
studies demonstrate that vaginal lactobacilli are generally non-
inflammatory when cultured on vaginal epithelium. L. jensenii,
and L. crispatus do not elicit a pro-inflammatory response
from vaginal epithelial cells (Figure 1A) (Libby et al., 2008;
Fichorova et al., 2011; Eade et al., 2012; Rose et al., 2012;
Yamamoto et al., 2013; Doerflinger et al., 2014). L. iners and
L. jensenii induce PRR-signaling but this does not lead to
an increase in secretion of pro-inflammatory mediators IL-
6 and IL-8 (Yamamoto et al., 2013; Doerflinger et al., 2014).
Although lactobacilli contain MAMPs that could potentially
activate TLRs, L. crispatus and L. jensenii significantly dampen
cytokine expression of IL-6, IL-8, and TNFα from vaginal
epithelial cells following addition of exogenous TLR agonists
(Rose et al., 2012). This suggests a role for commensal bacteria
in maintaining vaginal homeostasis through as yet unknown
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FIGURE 1 | The vaginal environment during alternative states of
eubiosis and BV. (A) During eubiosis, lactic acid-producing bacteria
acidify the vaginal milieu pH <4.5 (average ∼3.5) with lactic acid as the
predominant metabolite. Lactic acid potently inactivates STIs while lactic
acid-producers, such as Lactobacillus, generate a non-inflammatory
environment. (B) During BV, the vaginal environment has a lower redox
potential conducive to the growth of diverse anaerobic bacteria and
higher bacterial load. The concentration of mixed SCFAs and amines
also increase and is accompanied by loss of vaginal acidity pH >4.5.
The diverse anaerobic bacteria generate virulence factors which
compromise epithelial barrier integrity, degrade mucin and generate a
pro-inflammatory environment.
mechanism(s) for modulating cytokine responses. Since these
studies have largely focused on individual bacterial species,
further investigations are required to fully elucidate the mucosal
immune responses associated with the more complex CSTs
dominated by distinct lactobacilli including the specific effects
of lactic acid, as well as longitudinal studies to account for
the dynamic nature of the vaginal microbiota (Gajer et al.,
2012).
Bacterial Vaginosis, an Ecological Disorder
BV is a dysbiosis of the vaginal microbiota in reproductive-
age women with unknown etiology and poorly understood
pathogenesis. It is not known whether the bacteria commonly
associated with the syndrome are a cause or a consequence of
dysbiosis and unclear whether abnormal colonization is due to an
exogenous pathogen, opportunistic endogenous microbiota, or if
dysbiosis is triggered by vaginal microbiota unable to maintain
community function in the face of particular disturbances.
For women with lactobacillus-dominated microbiota, there is
a depletion of lactobacilli and an overgrowth of anaerobic
BV-associated bacteria (BVAB) (Figure 1B). The roles of different
lactobacilli in preventing or promoting the transition to dysbiosis
are an increasing area of investigation. As previously mentioned,
an L. crispatus-dominated microbiota rarely transitions to CST
IV-B (Table 1) containing BVAB, is not commonly found in
women with BV and is associated with a more acidic vaginal
milieu (Ravel et al., 2011; Gajer et al., 2012; O’Hanlon et al., 2013).
Conversely, an L. iners-dominated microbiota is encountered in
women regardless of BV status andmay offer less protection from
progression to BV. In this respect, a recent study by Macklaim
et al. (2013) found that L. iners differentially expressed 10% of
its genome when the vaginal ecosystem transitioned to dysbiosis.
Further investigation is required to determine if L. iners is not
antagonistic toward BVAB or less so than other lactobacilli,
why L. iners seems tolerant of dysbiosis and if it contributes to
dysbiosis.
BV-associated Bacteria (BVAB)
As well as a paucity of lactobacilli, BV is accompanied by
increased diversity and bacterial load of Gardnerella, Atopobium,
Prevotella, Megasphaera, Dialister, Sneathia, Leptotrichia,
Mobiluncus, Streptococcus, Bacteroides, Mycoplasma,
Clostridiales BVAB 1, 2, 3, and, several other bacteria (Fredricks
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et al., 2005; Wertz et al., 2008; Kim et al., 2009; Verstraelen et al.,
2009; Ling et al., 2010; Zozaya-Hinchliffe et al., 2010; Jespers
et al., 2012; Santiago et al., 2012; Srinivasan et al., 2012). BVAB
increase vaginal pH by generating mixed SCFAs and amines,
and are also capable of utilizing lactic acid as an energy source
(Figure 1B) (Spiegel et al., 1980; Wolrath et al., 2001; Macklaim
et al., 2013; Yeoman et al., 2013). Many of these BVAB are
common inhabitants of a eubiotic vaginal ecosystem but little is
known of synergistic or antagonistic effects between them, with
only Gardnerella and Prevotella displaying a synergism noted
by several studies (Biagi et al., 2009; Ling et al., 2010; Zozaya-
Hinchliffe et al., 2010; Ravel et al., 2011; Jespers et al., 2012;
Datcu et al., 2013). Furthermore, different isolates may represent
different strains/sub-strains that might be associated with BV.
For example, different isolates of Atopobium have been shown
to be resistant to metronidazole, the antibiotic used to treat BV
(Ferris et al., 2004a,b; De Backer et al., 2006). BV isolates of G.
vaginalis also have significant differences in genome content and
gene order that have variable metabolic and virulence capacity
(Harwich et al., 2010; Yeoman et al., 2010; Macklaim et al., 2013).
Interestingly, dispersed and cohesive forms of G. vaginalis have
also been identified, with the latter cohesive form associated
with the initiation and formation of biofilms hypothesized to
contribute to BV pathogenesis (Patterson et al., 2010; Swidsinski
et al., 2010). Atopobium and L. iners have also been implicated
in the formation of these biofilms (Swidsinski et al., 2005, 2008,
2010; Machado et al., 2013). However, further investigations
are required to elucidate the contribution of various
organisms in BV.
Altered Immune Modulation during BV
While BV does not cause overt clinical inflammation
characterized by redness and pain, it is nevertheless characterized
by a pro-inflammatory response in the vaginal mucosa
(Schwebke and Weiss, 2002; Mitchell and Marrazzo, 2014),
which is likely to have distinct characteristics based on the
bacterial communities responsible for BV. The cervicovaginal
immune response in women with BV has been examined in
several studies, which are reviewed in Mitchell and Marrazzo
(2014). Overall pro- and anti-inflammatory cytokine levels
tend to be elevated in women with BV (Cherpes et al., 2008).
However, the levels of specific cytokines and antimicrobial
peptides vary among studies, which have been proposed to be
due to several factors including differences in study population,
the bacterial communities responsible for BV, and the cross-
sectional design and small sample sizes. Nevertheless, in most
studies the pro-inflammatory cytokine, IL-1β is elevated and
the SLPI antimicrobial peptide is decreased in women with
BV while elevation of IL-6 and IL-8 is inconsistent among
studies (Mitchell and Marrazzo, 2014). In addition, vaginal
bacteria can modulate the innate immune response elicited by
epithelial cells with species-specific immune signatures (Libby
et al., 2008; Rose et al., 2012; Doerflinger et al., 2014). The
BVAB G. vaginalis and A. vaginae, when cultured on vaginal
or cervical epithelial cell monolayers and tissue models, elicit
a pro-inflammatory response by up-regulating the production
of cytokines (IL-6, IL-1β, TNFα, IL-8) and chemokines (e.g.,
RANTES, MIP-1β), some antimicrobial peptides (i.e., hBD-2,
defensins) and membrane-associated mucins (Figure 1B) (Libby
et al., 2008; Eade et al., 2012; Rose et al., 2012; Doerflinger et al.,
2014). These responses are similar to what is observed in women
with BV (Schwebke and Weiss, 2002; Hedges et al., 2006; Valore
et al., 2006; Mitchell and Marrazzo, 2014). In contrast, Prevotella
bivia, another BVAB, failed to elicit a pro-inflammatory response
when cultured on vaginal epithelium (Doerflinger et al., 2014)
indicating distinct pathogenicity of BV bacteria.
The Need to Improve Diagnosis of BV
The Amsel criteria and the Nugent score are the two main
methods for BV diagnosis. The Amsel criteria, contains four
criteria, at least three of which must be satisfied for a diagnosis
of BV; a vaginal pH >4.5, thin grayish homogenous discharge,
an amine odor upon addition of 10% potassium hydroxide
to vaginal discharge and the presence of sloughed epithelial
cells coated with BVAB (clue cells) in a Gram stained wet
mount (Amsel et al., 1983). In contrast, the Nugent score is
based on a Gram stain scoring method and is determined
by assessing Lactobacillus morphotypes present as large Gram-
positive bacilli, Gram-variable bacilli indicative of G. vaginalis
morphotypes and curved Gram-variable bacilli indicative of
Mobiluncus morphotypes (Nugent et al., 1991). A Nugent score
of 7–10 is a positive diagnosis of BV. The Nugent scoring method
is reported to have superior reproducibility and sensitivity
relative to the Amsel criteria (Sha et al., 2005a; Modak et al.,
2011); however, current diagnosis methods are biased in that
they rely on the simplistic concept that lactobacilli equate to
healthy vaginal microbiota and assessment occurs at a single
time point. Our current understanding of the microbiome
reveals that 20–30% of reproductive-age women have diverse
lactic acid-producing microbiota that are not lactobacilli and
that vaginal microbiota can experience dramatic transitions in
community composition over time without transitioning to
dysbiosis (Zhou et al., 2004, 2007, 2010; Ravel et al., 2011;
Gajer et al., 2012). Consequently, current diagnostics may have
confounded our current understanding of BV. Nonetheless, these
are the best currently available diagnostic methods and in the
future they are likely to be replaced by molecular quantification
and characterization as technology advances.
BV Treatment and Recurrence
In most women, BV will spontaneously resolve without
treatment (Hay et al., 1997; Koumans et al., 2007; Laghi et al.,
2014) however, treatment is recommended for symptomatic
women due to potential BV-associated complications. Current
recommended regimens include oral metronidazole (500mg)
twice a day for 7 days, metronidazole gel (0.75%) once a day
for 5 days or clindamycin cream (2%) for 7 days, in conjunction
with abstinence from sex or the use of condoms (CDC, 2010).
Antibiotic treatment is often efficacious but to varying degrees
in different women (Srinivasan et al., 2010). Recurrence is
frequently inevitable and because the etiology of BV is unknown,
it is unclear whether recurrence is due to antibiotic resistance,
re-inoculation, re-emergence of endogenous bacteria, or some
other disturbance leading to the loss of microbiota community
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function. Estimates indicate that BV will recur in 30% of women
within 3 months of antibiotic treatment and >50% of women
within 6 months (Hanson et al., 2000; Sanchez et al., 2004; Sobel
et al., 2006; Bradshaw et al., 2006a,b; Nyirjesy et al., 2007).
A number of studies have attempted to address the cause of
recurrent BV and suggest that antibiotic resistance and biofilms
may play a role (Beigi et al., 2004; Verstraelen et al., 2004;
Austin et al., 2005; Swidsinski et al., 2005, 2008, 2010)as well
as extravaginal reservoirs (El Aila et al., 2009; Marrazzo et al.,
2012; Petricevic et al., 2012; Santiago et al., 2012). Also, antibiotic
treatment of BV can severely disrupt the microbiota (Santiago
et al., 2012) and does not ensure that the microbiota will
return to its pre-BV state (Agnew and Hillier, 1995; Nyirjesy
et al., 2007). This suggests that whilst treatment may reduce
the abundance of BVAB the consequent ecological void may
allow for the re-emergence of opportunistic endogenous bacteria
or unimpeded re-inoculation with exogenous pathogens. The
antibiotic rifaximin is reported to overcome the limitations of
existing antibiotic therapy (Cruciani et al., 2012, 2013; Donders
et al., 2013) by restoring the vaginal community as well as
the metabolome (Laghi et al., 2014). Alternative strategies for
BV treatment such as oral and topical probiotics, which also
aim to restore vaginal community function, are undergoing
evaluation. However, the data are currently inconclusive, likely
due to heterogeneity in clinical trial methodology and study
endpoints, the administration route (oral/intravaginal), dosage,
and strains of probiotic bacteria used and if they were provided
as a cocktail or a single strain as well as the characteristics of the
study populations (Senok et al., 2009; Mastromarino et al., 2013;
Huang et al., 2014).
It is also important to consider that due to the nature
of BV diagnosis methods, such as the Nugent score, women
with non lactobacillus-dominated microbiota (CST IV) may
have been misdiagnosed with BV and this may contribute to
apparent BV recurrence and explain spontaneous BV resolution.
Furthermore, the high rates of BV recurrence are not surprising
when considering that the composition and abundance of BVAB
in each woman exhibits great variation (Fredricks et al., 2005;
Ravel et al., 2013; Yeoman et al., 2013) yet treatments are
not targeted to accommodate these differences. With current
technological advances it should be possible to stratify women
according to the profile of BVAB and tailor therapy for better
treatment outcomes.
BV-associated Complications and Sequelae
BV is of clinical significance due to the multitude of adverse
reproductive outcomes and increased risk of acquiring STIs. BV
is associated with preterm birth (Eschenbach et al., 1984; Gravett
et al., 1986; Kurki et al., 1992; Riduan et al., 1993; Hay et al.,
1994; Holst et al., 1994; McGregor et al., 1994; Hillier et al.,
1995; Wennerholm et al., 1997), pelvic inflammatory disease
(Ness et al., 2005), spontaneous abortion (Donders et al., 2000),
post-abortal infection (Larsson et al., 2000), and miscarriage
(Hay et al., 1994; Llahi-Camp et al., 1996; Ralph et al., 1999;
Oakeshott et al., 2002; Nelson et al., 2007); indicating that BVmay
predispose women to abnormal ascending colonization of the
upper reproductive tract. BV is also associated with an elevated
risk of acquiring STIs includingNeisseria gonorrhea (Morris et al.,
2001; Wiesenfeld et al., 2003; Brotman et al., 2010a; Gallo et al.,
2012), Chlamydia trachomatis (Morris et al., 2001; Wiesenfeld
et al., 2003; Schwebke and Desmond, 2007; Brotman et al., 2010a;
Gallo et al., 2012), Trichomonas vaginalis (Martin et al., 1999;
Brotman et al., 2010a, 2012), herpes simplex virus type-2 (HSV-2)
(Cherpes et al., 2003; Kaul et al., 2007; Nagot et al., 2007), human
papilloma virus (HPV) (Watts et al., 2005; Gillet et al., 2011) as
well as HIV (Sewankambo et al., 1997; Taha et al., 1998; Cu-Uvin
et al., 2001; Coleman et al., 2007; Atashili et al., 2008; Cohen et al.,
2012).
BV may facilitate the acquisition of STIs, through a variety
of mechanisms stemming from the production of factors and
metabolites that create a favorable environment for the growth
other organisms (Hedges et al., 2006; Beigi et al., 2007; Rose
et al., 2012; Yeoman et al., 2013; Doerflinger et al., 2014) whilst
reducing the capacity to inactivate exogenous pathogens due
to a loss of lactic acid and lactic acid-producing microbiota
(Figure 1B). In this regard, BVAB have been shown to increase
vaginal pH which would enable the survival of acid-labile
exogenous pathogens including most of the aforementioned STIs
a woman with BV is at increased risk of contracting (McGrory
et al., 1994; Brotman et al., 2010a; Graver and Wade, 2011;
Aldunate et al., 2013; Gong et al., 2014). In addition to increased
acquisition risks, the altered dynamics of the vaginal ecosystem
during BV (Figure 1B) may also facilitate the sexual transmission
of STIs, with several studies noting increased viral replication
and viral load in the CVF of women with HIV-1 and HSV-2
(Cu-Uvin et al., 2001; Cherpes et al., 2005; Cohn et al., 2005;
Sha et al., 2005b; Coleman et al., 2007; Mitchell et al., 2013) and
transmission of HIV to their male partners (Cohen et al., 2012).
In contrast, women with vaginal microbiota dominated by lactic
acid-producing bacteria negatively correlate with BV acquisition
(Skarin and Sylwan, 1986; Tamrakar et al., 2007; Srinivasan
and Fredricks, 2008; Zozaya-Hinchliffe et al., 2010) and have a
reduced risk of acquiring STIs including N. gonorrhea (Martin
et al., 1999; Wiesenfeld et al., 2003), C. trachomatis (Wiesenfeld
et al., 2003),T. vaginalis (Martin et al., 1999; Brotman et al., 2012),
and HIV (Martin et al., 1999).
Overall, several studies denote that acidic vaginal conditions
and lactic acid-producing microbiota are associated with reduced
susceptibility to STIs whereas BV, with an elevated pH and
reduction in lactic acid-producing bacteria, appears to increase
susceptibility (Figure 1). However, the maintenance of the
vaginal ecosystem and the development of dysbiosis remain a
mystery and the degree of protection afforded by distinct vaginal
communities requires further investigation. Furthermore, BV
symptoms are varied amongst women and these may reflect
different etiologies and or different pathogenesis mechanisms
leading to BV in the context of a woman’s unique genetic
determinants andmicrobiota. The characterization of microbiota
members has certainly enhanced our understanding of the
vaginal ecosystem but supplementary information regarding
microbiota metabolic activities and their impact on the
function and performance of the vaginal ecosystem is required
to gain a complete understanding of vaginal eubiosis and
dysbiosis.
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The Metabolome in Eubiosis and Dysbiosis
During the reproductive years the vaginal microbiome provides
a multifaceted primary defense mechanism against infections
whilst promoting favorable reproductive outcomes. One manner
in which this is achieved is the production of acid fermentation
products, primarily lactic acid, which acidifies the vagina through
the concerted effort of lactic acid-producing bacteria. Thus, the
production of lactic acid, together with host factors, deeply
impacts the resulting microbiota by excluding or selecting
community members (Figure 1A). Collectively, these members
generate the functional output of that particular community
thereby influencing resilience in the face of intrinsic and
extrinsic disturbances. A representation of both host and
microbial factors in the vaginal ecosystem is captured within
CVF. The metabolome, in particular SCFAs and amines, are
the most extensively studied components of this complex
medium.
Early Studies of CVF Metabolites Associated with
Eubiosis and BV
Early studies investigated SCFAs and amines in CVF through
a variety of chromatographic techniques in an effort to identify
metabolites associated with dysbiosis that could be used for
the diagnosis of a polymicrobial syndrome, then known as
non-specific vaginitis (NSV) (Gardner and Dukes, 1955; Spiegel
et al., 1980; Piot et al., 1982; Ison et al., 1983). The criteria later
established by Spiegel (Spiegel et al., 1983), Amsel (Amsel et al.,
1983), and Nugent (Nugent et al., 1991), determined that the vast
majority of NSV cases were actually BV. Overall, early studies in
healthy asymptomatic reproductive-age women found that lactic
acid was the predominant metabolite in CVF with relatively
small amounts of the SCFAs acetate, propionate, butyrate,
isobutyrate, succinate, formate, fumarate, valerate, and caproate
(Preti and Huggins, 1975; Spiegel et al., 1980; Piot et al., 1982;
Ison et al., 1983; Krohn et al., 1989; Stanek et al., 1992) as well
as trace amounts, if any, of the amines putrescine, cadaverine,
and spermidine (Chen et al., 1979, 1982; Sanderson et al., 1983;
Jones et al., 1994; Kubota et al., 1995; Wolrath et al., 2001). In
contrast, BV-associated metabolite profiles showed that lactic
acid was often dramatically decreased along with an increased
concentration and variety of SCFAs and amines that were more
prevalent in women with BV (Spiegel et al., 1980; Piot et al.,
1982; Ison et al., 1983; Jokipii et al., 1986; Krohn et al., 1989;
Stanek et al., 1992; Chaudry et al., 2004) as reviewed in Wolrath
et al. (2001).
The BV-associated SCFA profiles obtained using gas liquid
chromatography (GLC) prompted the development of a BV
marker based on the correlation of a high succinic:lactic acid
ratio and dysbiosis determined by fulfilling two of the following
criteria; pH >4.5, homogenous discharge, presence of clue cells
and amine odor (Spiegel et al., 1980). A peak ratio of =0.4
showed 86% sensitivity, 97% specificity for BV and 90% positive
predictive value, where the sensitivity could be increased to 90%
if propionate and butyrate peaks were detected. This method
was used with varying success to diagnose BV, with most studies
reporting 80–90% sensitivity and 80–97% specificity (Piot et al.,
1982; Ison et al., 1983; Gravett et al., 1986; Krohn et al., 1989).
Early studies also sought to assess changes in metabolite profiles
associated with the antibiotic treatment of BV and consistently
found a return to increased lactic acid with a concomitant
decrease in BV-associated SCFAs acetate, propionate, butyrate,
isobutyrate, succinate and caproate and, other organic acids
(Spiegel et al., 1980; Stanek et al., 1992; Chaudry et al., 2004) as
well as BV-associated amines (Chen et al., 1979, 1982; Sanderson
et al., 1983). Thus, the relative levels of lactic acid and SCFAs
in CVF often reflected the success or failure of antibiotic
treatment.
A paucity of lactobacilli in conjunction with increased
bacterial diversity and load was associated with altered
metabolite profiles of women with BV vs. those of healthy
asymptomatic women (Piot et al., 1982; Jokipii et al., 1986).
Many BVAB are known to produce several acid metabolites;
for example: Bacteroides (succinate-producers), Peptococcus
(butyrate- and acetate-producers), Clostridium and Gram-
positive cocci (caproate-producers) and, Dialister (propionate-
producer) (Spiegel et al., 1980; Debrueres and Sedallian, 1985;
Downes et al., 2003; Chaudry et al., 2004). Particular attention
was paid to G. vaginalis (acetate and succinate-producer),
because of the work of Gardner and Dukes (1955). However, G.
vaginalis was frequently cultured from women regardless of BV
status and the detection and quantity of acetate- or succinate was
not associated with G. vaginalis (Spiegel et al., 1980; Piot et al.,
1982). Holmes et al. (1985) employed an alternative approach
to ascertain whether the altered metabolic profile was due to
an unknown host determinant or microbial metabolism. Here,
the redox potential (Eh) at the vaginal epithelium was measured
in healthy asymptomatic women and women with BV, it was
hypothesized that vaginal microbiota would influence the redox
potential due to altered concentrations of organics acids that
form redox pairs (e.g., lactate/pyruvate and succinate/fumarate)
(Holmes et al., 1985). Women with BV were reported to have
a more reduced vaginal environment compared to healthy
asymptomatic women. Typically, redox potential varies by ±
60mV per pH unit but the difference between the two groups
was 262mV for 1 pH unit difference, indicating that pH alone
could not account for the altered redox potential. The difference
in redox potential was attributable to microbial metabolism
rather than a host determinant because antibiotic treatment
successfully increased the redox potential, similar to that of
healthy asymptomatic women. Notably, a more reduced vaginal
environment is conducive to the growth of anaerobes, which
increase in number and diversity during BV. However, as with
other BV-associated changes, this study could not conclude
whether the reduced environment was a cause or consequence
of dysbiosis.
It was hoped that important insights would be obtained into
microbial and host interactions during BV by assessing CVF in
eubiosis and dysbiosis. However, no clear association could be
made between specific BVAB and ensuing changes in metabolite
profiles. Nonetheless, these studies contributed to revealing BV
as a multifaceted syndrome associated with gross metabolic
changes in addition to dysbiotic microbiota and altered immune
regulation.
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Recent Studies of CVF Metabolites Associated
with Eubiosis and BV
Advances in molecular technology and metabolite detection are
now supplementing these early studies by characterizing the
complexity of a vaginal community, shared metabolic pathways
of community members and the metabolic output of microbiota.
As mentioned previously, the temporal dynamics of the vaginal
microbiota demonstrates that shifts in community members is
not necessarily a precursor to dysbiosis because some community
members exhibit functional redundancy and are able to maintain
lactic acid production (Gajer et al., 2012). For example, Gajer et al.
(2012) reported two women (Subjects 22 and 28) that maintained
lactic acid production despite a transition from L. gasseri to
Streptococcus or L. crispatus to L. iners. Conversely, long-term
changes in vaginal microbiota were associated with a depletion
of lactobacilli and an increase in BVAB with decreased lactic
acid and increased levels of succinate and acetate (Subjects 8 and
10). In this regard, ensuing molecular characterization has shed
some light on the relative importance of different lactobacilli as
well as taking into consideration the contribution of other lactic
acid-producing bacteria.
A study by Bai et al. (2012) employing pyrosequencing of
the 16S rRNA gene to determine microbial composition and
proton nuclear magnetic resonance (1H NMR) spectroscopy
for the metabolome, confirmed that lactic acid was the
predominant metabolite in women withmicrobiomes dominated
by lactobacilli. Generally, this study showed that 89% of women
with diverse microbiota resembling CST IV (Table 1) had
metabolic end-products in CVF consisting of 3–12% lactic acid
vs. womenwith L. crispatus-dominantmicrobiomes with 18–27%
lactic acid. However, it is thought that lactobacilli differ in their
metabolic output and relative contribution of lactic acid since
the abundance of lactic acid did not appear to correlate with
the abundance of a particular Lactobacillus species. This study
showed that L. crispatus dominatedmicrobiomes had some of the
highest levels of lactic acid and is consistent with previous studies
where L. crispatus has been associated with a more acidic vaginal
milieu (Ravel et al., 2011; O’Hanlon et al., 2013). However,
different levels of SCFAs were also observed in microbiomes
with different community composition, belonging to the same
CST. For example subject SO6 and SO4 both harbored CST I;
SO6 was dominated almost exclusively by L. crispatus with high
lactic acid levels while SO4 was dominated by L. crispatus, L.
iners, and L. jensenii and was accompanied by higher levels of
acetate and succinate. L. gasseri-dominated microbiomes were
associated with lower levels of lactic acid, consistent with the
findings of Ravel et al. (2011) citing a higher pH in CST II
(Table 1). Interestingly, subject SO2 harbored a microbiome with
high Nugent score composed of L. iners, Prevotella, Megasphaera,
and Lachnospiraceae and high levels of acetate and succinate;
yet, the levels of lactic acid produced were marginally higher
than that of subject SO1 with a low Nugent score and a
microbiome dominated by L. gasseri. These findings highlight the
variable metabolic output of different lactobacilli species as well
as demonstrating functional redundancy regarding lactic acid
production.
Alternatively, Yeoman et al. (2013) employed metabolomics
and a network-based approach to link particular metabolites with
vaginal community members in women with BV. Here, the loss
of lactic acid was the single most distinguishing feature of women
diagnosed with BV using the Nugent method. Interestingly, BV
was not identified as a single entity but rather two subtypes;
symptomatic BV type I (SVBI) associated with high levels of
acetate and high Nugent scores, and SBVII associated with high
levels of propionate and intermediate or low Nugent scores.
Major determinants for SBVI and SBVII were identified as
derivatives of lactic acid including 1,2-propanediol and acetate
both resulting from the degradation of lactic acid and 1-acetoxy-
2-propanol, which can be obtained via lipase activity from 1,2-
propanediol (Izquierdo et al., 2000; Oude Elferink et al., 2001).
Overall, a network-based approach implicated several BVAB
in BV symptomology, including malodor with the presence of
amines that were linked to Dialister, 2-methyl-2-hydroxybutyric
acid associated with discharge and linked to Mobiluncus and
diethylene glycol associated with pain which was associated
with G. vaginalis. Collectively, this study concurs with previous
suggestions that the etiologies and pathogenesis mechanisms of
BV may vary depending on the bacteria and metabolites present
in the context of a woman’s unique vaginal environment.
It is important to note that metabolic analyses are limited by
the ability to detect metabolites that are present in appreciable
amounts and primarily constitute the end-products of metabolic
pathways. Therefore, the important roles and interaction of
intermediate metabolites and pathways are not fully appreciated
and will likely require the combination of metabolomics with
metagenomics in future investigations. One such approach is
meta-RNA-seq employed by Macklaim et al. (2013) with the aim
of analyzing the differential expression of genes and pathways
in vaginal microbiota during eubiosis and dysbiosis. This study
assessed two healthy asymptomatic women, N4 and N30, with
different vaginal community types both largely dominated by
L. crispatus and two women, B27 and B31, with diverse vaginal
communities diagnosed with BV according to the Nugent score.
Subject B27 harbored microbiota dominated by L. iners followed
by L. crispatus, Prevotella, and Gardnerella while B31 contained
Prevotella, L. iners, Gardnerella, and Megasphaera. When the
gene expression of healthy asymptomatic women vs. women
with BV was analyzed by gene function in relation to linked
metabolic pathways, the two states were found to largely differ
in pathways for energy metabolism. In healthy asymptomatic
subjects dominated by L. crispatus, there was an up-regulation
of steps in the glycolytic pathway responsible for lactic acid-
production and lactic acid was predicted as the predominant
metabolite. In contrast, changes associated with BV included
the up-regulation of steps in the tri-carboxylic acid cycle and
oxidative phosphorylation as well as the up-regulation of the
enzymes butryl-coA-dehydrogenase and butyrate kinase, which
are predicted to increase succinate and butyrate, respectively.
Furthermore, many BVAB increased the expression of enzymes
presumably involved in carbohydrate/glycogen uptake and
metabolism. In addition, enzymes expressed by Prevotella amnii,
Dialister, and Megasphaera were linked to amine production.
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Overall, in healthy asymptomatic women who harbored L.
crispatus as the dominant organism, microbiota metabolism
was largely oriented toward the production of lactic acid that
is responsible for generating a protective acidic environment
(Figure 1A) (Macklaim et al., 2013; O’Hanlon et al., 2013).
In contrast, women with BV harbored less lactobacilli and
diverse microbiota geared toward the production of succinate
and butyrate as well as amines. Together these would generate
a vaginal environment with low redox potential conducive to the
growth of anaerobes as well as increased vaginal pH, potentially
allowing the survival of exogenous acid-labile pathogens and
or allow the growth of opportunistic endogenous microbiota
(Figure 1B).
Recent studies and cumulative knowledge over several
decades consistently show a dramatic loss of lactic acid in
BV, as well as increased prevalence and production of acetate,
propionate, butyrate and succinate, and amines (Table 3).
Further investigation is required to elucidate how these
metabolites are involved in microbiota and host interactions
and their roles in community function. This knowledge will
be essential for understanding dysbiosis and associated risks of
disease (Table 1) as well as determining appropriate prevention
and therapy for certain BVAB and metabolic profiles. In this
regard, the application of metagenomics holds great promise
particularly for a multifaceted polymicrobial syndrome such as
BV, which has resisted conventional analysis.
The Antimicrobial Properties of Lactic Acid
and SCFAs Produced by Vaginal
Microbiota in Eubiosis and Dysbiosis
Lactic acid is the predominant acid metabolite found in the CVF
of healthy asymptomatic women Table 3 (Preti and Huggins,
1975; Spiegel et al., 1980; Piot et al., 1982; Ison et al., 1983;
Krohn et al., 1989; Stanek et al., 1992; Bai et al., 2012; Macklaim
et al., 2013; Yeoman et al., 2013). Glycogen, and its breakdown
products (glucose and maltose) produced by the action of vaginal
α-amylase (Spear et al., 2014), is thought to be the primary
TABLE 3 | Shifts in CVF metabolite concentration in eubiosis compared to
the CVF of women with BV.
Acid/SCFA concentration Acid/SCFA concentration
during eubiosis [mM] during BV [mM]
Lactic ∼120a,b,e Lactate <20e
Acetic 0–4b,c,d,f Acetate <120a,c,d,f
Propionic <1 Propionate 2–4c
Butyric <1 Butyrate 2–4c
Succinic <1e Succinate <20e
aGajer et al. (2012).
bO’Hanlon et al. (2013).
cMirmonsef et al. (2011).
dMirmonsef et al. (2012c).
eAl-Mushrif et al. (2000).
fChaudry et al. (2004).
energy source used by lactobacilli during anaerobic glycolysis
that leads to lactic acid production (Figure 1A) (Paavonen, 1983;
Wilson et al., 2010). Further, high free glycogen levels and
lactobacilli in the vaginal lumen tend to correlate with low
vaginal pH (Mirmonsef et al., 2014). In stark contrast, glycogen
and lactic acid are depleted in women with BV (Mirmonsef
et al., 2012a), possibly due to increased glycogen consumption
by BVAB that would prevent regrowth of lactic acid-producing
bacteria (Figure 1B) (Mirmonsef and Spear, 2014).
Lactic Acid is a Potent Microbicide under
Hypoxic Vaginal Conditions but Hydrogen
Peroxide (H2O2) Is Not
Acidification of the vagina by lactic acid was originally
proposed as the primary antimicrobial mechanism by which
lactobacilli defend against reproductive tract pathogens
(Döderlein, 1892). However, the production of H2O2 by H2O2-
generating lactobacilli was subsequently favored as a prominent
antimicrobial factor present in the CVF of healthy asymptomatic
women (Klebanoff and Coombs, 1991; Klebanoff et al., 1991).
This was based on studies reporting that the prevalence of H2O2-
producing lactobacilli is lower in women with BV (Eschenbach
et al., 1989) and that H2O2-producing lactobacilli inactivate HIV
(Klebanoff and Coombs, 1991) and BVAB (Klebanoff et al., 1991)
While H2O2 is present at low concentrations in CVF, its ability
to inhibit microbes in the context of the reducing and hypoxic
vaginal environment has recently been cast into serious doubt
(O’Hanlon et al., 2010, 2011; Graver and Wade, 2011; Gong
et al., 2014). Specifically, studies with BVAB, N. gonorrhea and C.
trachomatis demonstrate that the primary microbicidal activity
under hypoxic vaginal conditions is due to lactic acid and not
H2O2 (O’Hanlon et al., 2010; Graver and Wade, 2011; Gong
et al., 2014).
It was only recently that the key role of lactic acid in
vaginal acidification was convincingly demonstrated (O’Hanlon
et al. (2013). Here, 64 CVF samples obtained from 56 women
with lactobacillus-dominated flora as determined by low
Nugent scores (0–3), were analyzed to reveal a strong inverse
correlation between vaginal pH and lactic acid concentration.
Quantitation of physiological concentrations of lactic acid and
pH, measured under conditions recapitulating the hypoxic
vaginal environment, demonstrated an average pH of 3.5 ±
0.3 (mean ± SD) with a range of 2.8–4.2, and an average
total lactic acid concentration of 1.0% ± 0.2% w/v (O’Hanlon
et al., 2013). These data differ markedly from previous studies
that reported a higher eubiotic vaginal pH of 4.2 (Owen and
Katz, 1999). Overall, this study demonstrates that lactic acid,
in conditions that resemble a eubiotic vaginal environment, has
a major role in acidifying the vagina to pH values lower than
previously described. Lactic acid can exist as protonated lactic
acid or the unprotonated lactate anion, which is determined
by the acid dissociation constant (pKa 3.9) (Figure 2). Under
neutral conditions, the lactate anion predominates whereas in an
acidic vaginal milieu, undissociated lactic acid predominates and
it is this form that is endowed with microbicidal and virucidal
activity (O’Hanlon et al., 2011; Aldunate et al., 2013). Given that
lactic acid is more abundant at lower pH and taken together
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FIGURE 2 | Protonated lactic acid exists in equilibrium with the
un-protonated lactate anion, which is determined by the acid
dissociation constant (pKa 3.9). In healthy asymptomatic women of
reproductive age with low vaginal pH, lactic acid predominates which is the
microbicidal and virucidal form with immune modulatory activity. In contrast,
the lactate anion, which does not have microbicidal or virucidal activity,
predominates in women with bacterial vaginosis with a neutral vaginal pH.
with the latest physiological levels of lactic acid and vaginal pH
(O’Hanlon et al., 2013), the microbicidal form of lactic acid
is calculated to be 11-fold more concentrated in women with
lactobacillus-dominatedmicrobiota and likely more important as
a microbicide than otherwise indicated by prior research.
Lactic Acid Potently Inactivates BV-associated
Bacteria
Many pathogens are well recognized as being susceptible to acid
but the potential role of lactic acid in the vaginal ecosystem
and its specific antimicrobial effects have not been extensively
characterized. The in vitro studies performed by O’Hanlon
et al. (2011) demonstrate that lactic acid at physiological
concentrations (55–111mM) and at pH 4.5 inactivates 17
different species of BVAB including G. vaginalis and Atopobium
vaginae while not affecting the viability of the four main vaginal
lactobacilli, L. jensenii, L. gasseri, L. crispatus, and L. iners, even
at a concentration 1110mM (10% w/v) that is 10 times above
physiological levels (O’Hanlon et al., 2011). A potent ∼106-fold
decrease in viability was observed for all BVAB treated with
111mM (1% w/v) lactic acid, pH 4.5 for 2 h at 37◦C (O’Hanlon
et al., 2011). In contrast, treatment with lactic acid at pH 7.0
is not microbicidal indicating that the activity is pH-dependent
and is mediated by protonated lactic acid not the lactate anion
(Figure 2) (O’Hanlon et al., 2011). Lactic acid is significantly
more potent in inactivating BVAB compared to media acidified
to pH 4.5 with an inorganic acid (i.e., HCl) or with acetic acid
at concentrations corresponding to physiological levels of lactic
acid (55–111mM) (O’Hanlon et al., 2011).
Both lactic- and acetic acids are weak membrane permeant
acids (Kashket, 1987). However, acetic acid is smaller and
more protonated than lactic acid at an equivalent pH, due
to its higher acid dissociation constant (pKa ∼4.8). Therefore,
it would be expected to acidify the bacterial cytosol and
lead to cell death more rapidly. However, the antibacterial
activity of lactic acid is markedly more potent than acetic
acid suggesting that it might act by additional mechanisms
such as disturbing bacterial membranes (Alakomi et al., 2000).
The relatively weak antimicrobial activity of acetic acid is of
importance due to its predominance over lactic acid during BV
(Table 3) and suggests that the loss of lactic acid leads to altered
competitive dynamics in the vaginal environment resulting in
less inhibition of endogenous opportunistic bacteria and BVAB
(Figure 1B).
Lactic Acid Potently Inactivates HIV
It is well recognized that HIV is acid-labile as determined
using a variety of acids including HCl, phosphate/citrate buffers,
acetic acid or lactic acid to inactivate virus (Martin et al.,
1985; Ongradi et al., 1990; Kempf et al., 1991; O’Connor et al.,
1995; Connor, 2006). However, only recently has the HIV
virucidal activity of lactic acid at physiological concentrations
been directly compared to other acids including acetic acid
that predominates during BV. We have shown that at a typical
vaginal pH of 3.8, 1% (w/w) L-lactic acid is significantly more
potent and rapid in inactivating HIVBa−L, a CCR5-coreceptor
using laboratory strain, and transmitted-founder strains HIV-
1RHPA.c/2635 and HIV-1CH058.c/2960, known to have established
a productive infection in a new host (Keele et al., 2008;
Salazar-Gonzalez et al., 2009), compared to 1% (w/w) acetic
acid and acidity alone (HCl), all adjusted to pH 3.8 (Aldunate
et al., 2013). In addition, lactic acid has broad-spectrum anti-
HIV activity where complete inactivation of different HIV-1
subtypes and HIV-2 was achieved with ≥0.4% (w/w) L-lactic
acid (Aldunate et al., 2013). L-lactic acid at 1% (w/w) also
maximally inactivates HIV-1 in the presence of cervicovaginal
secretions and seminal plasma (Aldunate et al., 2013). Like the
BVAB lactic acid inactivation studies (O’Hanlon et al., 2011),
the anti-HIV activity of L-lactic acid is abolished at neutral
pH, indicating that lactic acid and not the lactate anion is
virucidal (Figure 2). HIV-1 inactivation is irreversible since loss
of infectivity is observed even after adjusting the pH of the
medium to neutral following virus acid treatment (Aldunate
et al., 2013).
Intriguingly, physiological levels of lactic acid at pH 4.0
do not disrupt viral particles (Lai et al., 2009). The superior
potency of lactic acid compared to other acids is similar
to findings with BVAB suggesting a common antimicrobial
mechanism (O’Hanlon et al., 2011) i.e., permeabilization of the
lipid membrane (Alakomi et al., 2000). However, the mechanism
by which lactic acid inactivates HIV-1 is likely to be multifactorial
and could include targeting of viral or virion-incorporated host
proteins leading to loss of function by denaturation (Tang
et al., 2003). In this regard, the HIV-1 virucidal activity of
the L-lactic acid isomer is 17-fold greater than D-lactic acid
at the threshold concentration of 0.3% (w/w) and pH 4.0
(Aldunate et al., 2013), suggesting a protein target. Apart from
the anti-HIV activity of lactic acid, the presence of distinct
ratios of the L- and D-lactic acid isomers in cervicovaginal
mucus has been implicated as a surrogate marker for a vaginal
microbiota factor that hinders and traps viral particles, which
could impair the ability of the virus to reach target cells
in the vaginal epithelium (Lai et al., 2009; Shukair et al.,
2013).
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Whilst knowledge about the antimicrobial activity of lactic-
and acetic acid is increasing, very little is still known with
regards to the antimicrobial activity of propioniate, succinate and
butyrate, which are increased in concentration and prevalence in
women with BV. So far, our findings suggest that a high level
of vaginal lactic acid, at concentrations generated by eubiotic
microbiota, is a potent virucide whereas SCFAs at BV-associated
concentrations and pH do not lead to any detectable HIV
inactivation (Aldunate et al., 2014). Demonstration of potent
virucidal activity of lactic acid supports its role in defending
against viral pathogens such as female-to-male and mother-to-
child transmission of HIV (Frank et al., 2012) by reducing vaginal
shedding of infectious virus. The virucidal activities of lactic acid
may explain in part the inverse correlation observed between
HIV genital shedding in women and the presence of Lactobacillus
(Sha et al., 2005b; Borgdorff et al., 2014) although this needs
to be proven. In contrast, the role of lactic acid in mitigating
male-to-female transmission of HIV is not immediately obvious.
The antiviral activity of lactic acid is pH-dependent and semen
deposited into the vaginal lumen increases pH to neutral (Fox
et al., 1973), which could attenuate the anti-HIV activity of lactic
acid (Aldunate et al., 2013). Antiviral efficacy of lactic acid in
this context would depend on the ability of resident lactobacilli
to rapidly acidify the vaginal lumen (Boskey et al., 1999) before
cell-free or cell-associated HIV are able to migrate through the
mucous layer and squamous vaginal epithelium and ectocervix;
or transcytose/transmigrate through the columnar epithelium of
the endocervix to be able to reach target cells (Cone, 2014).
Lactic Acid Potently Inactivates HSV-2
Women with BV are also at increased risk of acquiring HSV-2
(Cherpes et al., 2003), which is a cofactor for HIV acquisition,
suggesting that lactobacilli and their product(s) might have a role
in blocking this viral STI. In this regard lactobacilli inhibit HSV-
2 replication through multiple effects. These include inhibiting
viral entry and replication, which is related to the adhesion
capacity of the lactobacillus strain, and the secretion of lactic
acid that has HSV-2 virucidal activity and also inhibits virus
replication by a virucidal-independent mechanism (Dimitonova
et al., 2007; Conti et al., 2009). Similar to HIV, physiological
concentrations of lactic acid (55–111mM) at low pH (4.0) but
not neutral pH, cause potent and irreversible HSV-1 and HSV-2
inactivation (Conti et al., 2009; Isaacs and Xu, 2013). However,
unlike HIV, culture medium acidified to the same pH with HCl
produces similar levels of HSV-2 inactivation as lactic acid (Conti
et al., 2009). Although this observation needs to be confirmed,
it suggests that the HIV virucidal mechanism of lactic acid is
distinct from HSV-2.
Immune Modulatory Effects of Lactic Acid
and SCFAs Associated with Eubiosis and
Dysbiosis
The immunemodulatory effects of vaginal microbiota, that could
prevent or promote susceptibility to infection by reproductive
tract pathogens, may in part be mediated through the production
of organic acid metabolites including lactic acid as well as acetate,
propionate, butyrate, and succinate (Kantor et al., 2009; Ravel
et al., 2011; Bai et al., 2012; Gajer et al., 2012; Das et al., 2015).
The critical role of microbiota metabolites in shaping the host
mucosal immune response and for limiting inflammation in the
context of an environment densely colonized with bacteria has
gained prominence in studies focused on the gastrointestinal
mucosa (Maslowski et al., 2009; Arpaia et al., 2013; Furusawa
et al., 2013; Arpaia and Rudensky, 2014). Similar to the gut,
the vaginal mucosa is colonized with mutualistic bacteria. The
metabolite composition of CVF may be indicative of microbiota
with diverse taxonomic compositions but representing similar
functional states that could be informative as biomarkers for
distinct immune effects on the host. However, little is known
about the immune modulatory effects of SCFA metabolites
produced by vaginal microbiota in the context of the unique and
acidic vaginal environment.
Immune Modulatory Effects of Lactic Acid
Immune modulating properties have been ascribed to L-
lactic acid (Shime et al., 2008; Mossop et al., 2011; Witkin
et al., 2011). Studies in the cancer field demonstrate that L-
lactic acid produced by tumor cells generates a mildly acidic
microenvironment (pH 6.0–6.5) that promotes tumor survival
and metastasis by directly mediating immunosuppressive effects
via decreased cytotoxic T cell function, monocyte function,
dendritic cell maturation, and cytokine production from immune
cells (Gottfried et al., 2006; Fischer et al., 2007; Goetze et al., 2011;
Choi et al., 2013). By contrast, in the presence of TLR2 and TLR4
ligands, L-lactic acid produced from tumors promotes the IL-
23/IL-17 pro-inflammatory pathway in monocyte/macrophages
(Shime et al., 2008). More recent studies reveal that treatment
with L-lactic acid at 15mM followed by lipopolysaccharide
(LPS), a TLR4 agonist, increases the production of IL-23 from
human PBMCs compared with LPS treatment alone and this
may lead to preferential stimulation of Th17 T-lymphocytes
(Table 2) (Witkin et al., 2011). Notably, induction of IL-23 was
not observed when L-lactic acid was tested at neutral pH or when
HCl was substituted for L-lactic acid indicating that potentiation
of this cytokine was not due to acidity alone (Witkin et al.,
2011). However, the pH values (7.0 to 6.4) these authors report
for L-lactic acid concentrations ranging from 30 to 60mM are
inconsistent with our report that 30mM lactic acid (∼0.3%
L-lactic acid) acidifies culture medium to pH 3.9 (Aldunate
et al., 2013). All together, these studies suggest that in the
context of conventional immune cells, L-lactic acid mediates
anti-inflammatory or pro-inflammatory effects depending on the
experimental conditions.
L-lactic acid also elicits immune mediator release from the
human vaginal epithelial cell line, VK2/E6E7, in the presence
of the viral TLR3 agonist polyinosinic acid: cytidylic acid [poly
(I:C)] (Mossop et al., 2011) (Table 2). L-lactic acid (at 15mM)
and TLR3 ligand treatment increased the production of the pro-
inflammatory immune mediators IL-8 and IL-1β in a standard
tissue culture plate setup (Mossop et al., 2011). Once again,
the effect was reported to be dependent on treatment with L-
lactic acid at acidic pH, and was not recapitulated with acetic
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acid, another smaller acid metabolite that is produced by BVAB
(Mossop et al., 2011). These effects appear to be at odds with
the reported anti-inflammatory and non-inflammatory effects
of vaginal lactobacilli (Kyongo et al., 2012; Rose et al., 2012;
Yamamoto et al., 2013; Doerflinger et al., 2014). Therefore,
we propagated the VK2/E6E7 epithelial cell line in transwell
culture conditions (Hearps et al., 2014) and performed a direct
comparison to standard tissue culture plate conditions described
by Mossop et al. (2011). Our study demonstrates that 0.3% L-
lactic acid at pH 3.9 causes total cell death when VK2/E6E7 cells
were cultured in standard tissue culture plates (Hearps et al.,
2014) suggesting that toxicity may contribute to altered cytokine
production. Another plausible explanation for the disparate
results in these two studies is that L-lactic acid confers distinct
immune effects at levels approaching physiologic concentrations
(55–111mM) and pH found in a healthy asymptomatic vagina.
Further work is needed to define the impact of lactic acid and
SCFAs at physiologic pH found in eubiosis and dysbiosis on
immune mediators produced by vaginal and cervical epithelial
cells and how this affects susceptibility to reproductive tract
infections.
Immune Modulatory Effects of BV-associated
SCFAs
The effect of SCFAs produced by gut microbiota on innate
immune function and epithelial integrity has been extensively
studied (Macia et al., 2012; Arpaia and Rudensky, 2014). In the
gut, SCFAs have an anti-inflammatory role by suppressing the
production of pro-inflammatory cytokines through inhibition
of NF-κB signaling and histone deacetylase (HDAC) (Segain
et al., 2000; Luhrs et al., 2002a,b; Tedelind et al., 2007; Cox
et al., 2009; Maslowski et al., 2009; Arpaia and Rudensky, 2014).
In stark contrast to the gut, SCFAs in the vagina appear to
be pro-inflammatory in women with BV (Mirmonsef et al.,
2012c). The SCFAs, acetate and butyrate, but not propionate at
high concentrations (20mM) tested at neutral pH induce the
production of pro-inflammatory cytokines IL-8, TNFα, and IL-
1β from human peripheral blood mononuclear cells (PBMCs)
and potentiated pro-inflammatory cytokine responses to TLR2
and TLR7 ligands at low concentrations (≤2mM) (Table 2)
(Mirmonsef et al., 2012c). The apparent discordant immune
effects of SCFAs in the gut compared to BV-related studies could
be ascribed to inherent differences in these organs including
cell-type, SFCA concentration, and pH (Cavaglieri et al., 2003;
Bailon et al., 2010; Mirmonsef et al., 2012c) which would alter
the ratios of protonated vs. unprotonated forms of the acids
that can have different biological functions (O’Hanlon et al.,
2011; Witkin et al., 2011; Aldunate et al., 2013). In addition, the
pro-inflammatory response elicited by BV-associated SCFAs is
consistent with a similar pro-inflammatory response produced
by BVAB when grown on vaginal epithelial cells in vitro (Libby
et al., 2008; Eade et al., 2012; Rose et al., 2012; Doerflinger
et al., 2014), indicating that these metabolites may contribute
to the sub-clinical inflammatory state observed in women
with BV.
While SCFAs appear to promote a pro-inflammatory response
in PBMCs under defined physiological conditions that are
relevant to BV, a very limited number of studies have attempted
to explore their direct immune modulatory role in dysbiosis.
Initial work has primarily assessed the effect of various SCFAs on
neutrophil polymorphonuclear leukocytes (PMNLs), important
for mounting an inflammatory response by recognition of
chemical signals that enable their migration to the appropriate
site for phagocytosis (Al-Mushrif et al., 2000). Notably, BV is
characterized by sub-clinical inflammation accompanied with
the absence of neutrophil PMNLs (Cauci et al., 2003). It was
thought that a variety of SCFA metabolites could be virulence
factors that inhibit neutrophil PMNL and monocyte migration
thereby enabling the unrestricted growth and establishment of
BVAB. Initial work assessed the BVAB Bacteroides a known
succinate-producer and reported that succinate could inhibit
both the chemotactic and phagocytic responses of neutrophil
PMNLs (Rotstein et al., 1985). Likewise, another study assessed
the effect of pure and BVAB derived lactate, acetate and succinate
on a monocytic cell line (MonoMac 6) as well as human
monocytes (Al-Mushrif et al., 2000). This study reported that
succinate exhibited the highest inhibition of chemotaxis followed
by acetate with significant but relatively less inhibition, in a dose
dependent manner. In contrast lactic acid did not significantly
inhibit monocyte chemotaxis. Similar trends were seen in both
the monocytic cell line as well as fresh human monocytes. In
addition, Prevotella and Mobiluncus broth cultures as well as
CVF from women with BV both contained high concentrations
of succinate and acetate that also demonstrated monocyte
chemotaxis inhibition. In contrast, Lactobacillus broth cultures
as well as the CVF from women with lactobacillus-dominated
microbiota showed no inhibition of monocyte chemotaxis (Al-
Mushrif et al., 2000). Overall, these studies suggest that SCFAs
produced by BVAB may contribute to BV pathogenesis by acting
as virulence factors that prevent the migration of immune cells
capable of generating an inflammatory response and this may in
turn allow the establishment of BVAB.
Immune Modulatory Effects of BV-associated SCFAs
on HIV
Several studies have focused on the mechanisms by which
the sub-clinical inflammation of BV and BV-associated SCFAs
could increase the risk of acquiring STIs, with a particular
focus on HIV. The main proposed mechanisms include altered
innate mucosal immunity leading to reduced barrier integrity
of the vaginal epithelium (Nazli et al., 2010) and the activation
and recruitment of HIV target cells to the genital mucosa
(Kantor et al., 2009; Thurman and Doncel, 2011; Mirmonsef
et al., 2012b; Das et al., 2015). BVAB could promote a pro-
inflammatory vaginal environment through the production of
SCFAs (Mirmonsef et al., 2012c). In the case of HIV, SCFAs such
as butyrate/butyric acid with known HDAC inhibitory activity
(Imai et al., 2012), could promote establishment of infection
in the vaginal mucosa through activation of transcriptionally
silenced HIV proviral and episomal DNA (Kantor et al., 2009;
Das et al., 2015) in resting CD4+ T cells, that mainly comprise
the small founder population during the initial phases of
HIV infection (Zhang et al., 1999; Haase, 2011). Succinate,
another BV-associated metabolite, has been shown to increase
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HIV expression in monocytes infected with HIVBa−L and
cells differentiated with either granulocyte-macrophage colony-
stimulating factor (GM-CSF) or macrophage colony-stimulating
factor (M-CSF) (Graham et al., 2013). The authors proposed
that this might contribute to increased viral shedding in
the CVF of HIV positive women with BV. In this study,
succinate was also the only metabolite that increased IL-8
levels relative to lactic acid, propionate, and butyrate which
may contribute to pro-inflammatory conditions (Graham et al.,
2013). A pro-inflammatory milieu would also lead to activation
and recruitment of HIV target cells to the founder population,
amplification of virus replication in the lower reproductive tract,
and subsequent virus spread to the periphery (Haase, 2011).
Since BV is associated with an increased risk of STI
acquisition, eliminating BV could indirectly protect against
STIs. This could be achieved by promoting vaginal colonization
with lactic acid-producing bacteria that compete for binding
sites on vaginal epithelium and that produce antimicrobial
factors, including lactic acid, to selectively suppress the growth
of BVAB (Joo et al., 2011; O’Hanlon et al., 2011). However,
further investigation is warranted regarding the contribution of
BV-associated SCFAs and their immune modulatory effect on the
vaginal epithelium remains to be elucidated.
Biomarkers for BV
Recently, our understanding of the complex vaginal ecosystem
has evolved dramatically in regards to microbiota composition,
metabolic output and related immunological changes in eubiosis
and dysbiosis. Yet, by its current definition BV remains a
relatively non-specific marker of risk for a multitude of adverse
sexual and reproductive outcomes. To date, the limited studies
that have sought to identify biomarkers specific for BV have
primarily involved analysis of the CVF proteome in relation to
outcomes of BV-associated reproductive sequelae (Balu et al.,
2003; Dasari et al., 2007; Kolialexi et al., 2008; Shah et al., 2009).
However, based on knowledge we have put forward in this review,
we believe that bacterial metabolites distinct for alternative states
of eubiosis and dysbiosis are excellent biomarker candidates and
should be a focus of future studies regarding BV biomarker
development.
Major differences in metabolite concentration are consistently
associated with a eubiotic state largely dominated by lactic acid
vs. dysbiosis characterized by decreased lactic acid and increased
mixed SCFAs and amine production, as well as increased vaginal
pH (Figure 1, Table 3) (Spiegel et al., 1980; Stanek et al., 1992;
Wolrath et al., 2001; Ravel et al., 2011; Yeoman et al., 2013).
Microbiota metabolites as biomarkers for BV have the advantage
that they reflect changes in vaginal microbiota that are associated
with BV but overcome the difficulty of attempting to link
specific bacterial species/strains, with uncharacterized metabolic
capacities that may be functionally redundant. Notably, attempts
to correlate specific bacteria with the metabolic output of the
polymicrobial microbiota in BV have not been successful in
the past and will be complicated by the presence of diverse
microbiota (CST IV) in reproductive-age women. Furthermore,
the presence of increased mixed SCFAs can influence vaginal
redox potential and may indicate a reduced vaginal environment
that favors the overgrowth of BV-associated anaerobes in
addition to signaling immunological changes in the vaginal
ecosystem that may contribute to BV pathogenesis.
Currently, the different SCFA profiles associated with eubiosis
and dysbiosis may have some utility as biomarkers that
complement established BV diagnostic methods by identifying
true cases of BV rather than women that are diagnosed with
BV because they harbor a diverse non lactobacillus-dominated
microbiota or because the microbiome was transitioning at the
time when BV was diagnosed. In this respect, Gajer et al. (2012)
showed that the transitioning of vaginal community composition
was possible whilst maintaining lactic acid production and
that only long-term changes in microbiota composition were
associated with changes in metabolite profiles (Gajer et al., 2012).
Furthermore, Laghi et al. (2014) assessed the metabolome of
women diagnosed with BV and found that those with a high
lactic acid content vs. BV-associated mixed SCFAs, at the time
of a positive BV diagnosis, were likely to experience spontaneous
remission in the absence of treatment, indicating that these were
not true cases of BV. The application of metabolites as markers
to determine the probability of spontaneous remission could
identify women whose microbiota are in a state of transition
but not necessarily transitioning to BV and would prevent the
unnecessary use of antibiotics that may severely impact the
microbiome and promote BV as well as contributing to antibiotic
resistance. The assessment of metabolites in CVF may also
be used to determine the efficacy of BV treatment and the
probability that BV recurrence will occur by tracking whether
lactic acid production has increased during and after antibiotic
treatment and, could aid in determining whether a different
antibiotic or regimen is required for better treatment outcomes.
It has been shown that women that experienced BV persistence
and BV recurrence did not have significantly increased lactic acid
levels during or following treatment (Spiegel et al., 1980; Laghi
et al., 2014).
It is envisioned that future studies will use vaginal metabolic
profiles to identify distinct subtypes of BV and associated
microbial groups/subsets. These biomarkers could be used
for stratifying women with a particular type of metabolic
profile of BV for treatment with targeted antibiotics as well
as promoting the development of treatments tailored to
each subtype. Indeed, one study by Yeoman et al. (2013)
has already employed metabolomics to identify two distinct
symptomatic BV metabotypes linked with certain organic
acids and certain bacteria, implicated in BV symptomology.
Meanwhile, metagenomics studies are shedding light on changes
in bacterial metabolism in respective states of eubiosis and
dysbiosis and are aiming to link these with the differential
expression of genomic content in specific vaginal microbiota
with common functional pathways (Macklaim et al., 2013). In
addition, it is proposed that different metabolite profiles may
not only be associated with but also contribute to increased or
decreased periods of disease risk and reproductive complications
over time (Table 1). The proper identification and treatment
of these women would be a crucial step in improving their
reproductive outcomes and reducing their risk of acquiring STIs.
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Conclusions
Presently, the development of metabolic biomarkers specific
for BV requires further investigation and will be challenging
given the heterogeneity of vaginal microbiota and research gaps
regarding BV etiology and pathogenesis in addition to the role of
host determinants in eubiosis and dysbiosis, which have not been
extensively studied. Moreover, these metabolites will have to be
distinct to each state of eubiosis and dysbiosis and be consistently
present in women experiencing each state. Yet, to date there
has been no large-scale study assessing BV-associated SCFAs
in representative groups of reproductive-age women. Further
investigation is also required to elucidate changes in metabolic
pathways, redox homeostasis, and inflammatory pathways so that
wemay understand the biological implications of increased SCFA
concentrations in the vaginal ecosystem. There are also likely to
be amultitude of bacterial and hostmetabolites and antimicrobial
factors in the vaginal milieu that contribute to protection or
contribute to BV symptomology and pathogenesis, which will
need to be elucidated.
The shift from a simplistic paradigm where lactobacilli equate
to vaginal health, to a greater awareness of vaginal ecosystem
complexity has in part been fuelled by advancing technologies
enabling the study of polymicrobial syndromes, such as BV,
that withstand conventional analysis. We now know that
lactobacilli are the most prevalent species in reproductive-age
women. However, there are a significant number of women that
harbor diverse microbiota that may also maintain community
performance. Cumulative interdisciplinary knowledge suggests
that allelopathic lactic acid-producing microbiota are key species
in shaping vaginal communities and maintaining community
performance associated with decreased risk of adverse sexual and
reproductive health outcomes. Importantly, the demonstration
that lactic acid has inherent microbicidal, virucidal, and immune
modulatory properties suggests that protection of the vaginal
environment extends beyond a mere role of vaginal acidification.
Lactic acid is present in high ∼110mM concentrations in
eubiosis and is far more abundant than other antimicrobial
peptides and protective factors that have been studied more
extensively, and is a primary determinant of the state of the
vaginal environment. Lactic acid certainly warrants further
investigation particularly in relation to BV-associated SCFAs,
which replace lactic acid, and appear to increase BV-associated
risks. A more holistic understanding of BV is likely to
spur new strategies that may block or modify certain BV-
associated metabolites with a view to promote vaginal health
and reinforce/maintain a protective vaginal ecosystem that will
prevent the development of BV. Given the protective actions
of lactic acid produced by vaginal microbiota, discovering how
BVAB or host factors cause the loss of lactic acid-producing
microbiota and episodes of BV, may be critical to developing
methods that maintain eubiosis. Lastly, the potent virudical and
microbicidal functions of lactic acid generated by lactic-acid
producing vaginal microbiota, strongly suggest that strategies to
promote and maintain lactic acid-producers such as lactobacilli,
perhaps by sustained delivery of lactic acid or the effective
administration of probiotic lactobacilli, may lead to improved
sexual and reproductive health outcomes.
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